TY - JOUR
T1 - 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma
T2 - how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
AU - Musto, Pellegrino
AU - Engelhardt, Monika
AU - Caers, Jo
AU - Bolli, Niccolo'
AU - Kaiser, Martin
AU - van de Donk, Niels W. C. J.
AU - Terpos, Evangelos
AU - Broijl, Annemiek
AU - Fernández de Larrea, Carlos
AU - Gay, Francesca
AU - Goldschmidt, Hartmut
AU - Hajek, Roman
AU - Vangsted, Annette Juul
AU - Zamagni, Elena
AU - Zweegman, Sonja
AU - Cavo, Michele
AU - Dimopoulos, Meletios A.
AU - Einsele, Hermann
AU - Ludwig, Heinz
AU - Barosi, Giovanni
AU - Boccadoro, Mario
AU - Mateos, Maria Victoria
AU - Sonneveld, Pieter
AU - San-Miguel, Jesus
PY - 2021/11
Y1 - 2021/11
N2 - According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and
AB - According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and
U2 - 10.3324/haematol.2021.278519
DO - 10.3324/haematol.2021.278519
M3 - Review article
C2 - 34261295
SN - 0390-6078
VL - 106
SP - 2799
EP - 2812
JO - Haematologica
JF - Haematologica
IS - 11
ER -